Compare ING Groep NV (ING) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Zimmer Biomet Holdings Inc — how do they compare? ING Groep NV trades at $33.36 (market cap $93.76B), while Zimmer Biomet Holdings Inc trades at $89.19 (market cap $16.95B). The key difference: ING Groep NV is far larger — about 5.5× Zimmer Biomet Holdings Inc's market cap, and ING Groep NV pays the higher dividend (3.95%). Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 94 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| ING | ZBH | |
|---|---|---|
Market Cap | $93.76B | $16.95B |
Volume | 4,620,220 | 2,505,240 |
Sector | Financials | Health |
52-Week High | $37.27 | $103.98 |
52-Week Low | $23.66 | $79.58 |
Typical Hold Time | 94 Days | 89 Days |
Enterprise Value | $236.48B | $24.02B |
Dividend Yield | 3.95% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $33.37, down 1.62% on the day, with a bearish technical signal from moving averages and oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.79 exceeding the $0.75 estimate. Revenue for 2025 reached $22.90 billion, with a net income margin of 28.34%, though cash flow trends show persistent net outflows. Analyst consensus is bullish with 11 buy ratings and no sell recommendations.
The outlook for ING is supported by raised ROE targets and organic growth initiatives, but risks include negative cash flows and regulatory scrutiny. The stock offers value with a P/E of 12.86 and dividend yield, yet investors face headwinds from operational cash burn and macroeconomic sensitivity.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
